Trial Profile
A Pilot Trial to Evaluate the Molecular Effects of RO4929097 as Neoadjuvant Therapy for Resectable Stage IIIB, IIIC or IV Melanoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs RG 4733 (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 30 Jan 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Dec 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov.